

1 **Study Title:** The Emmetropization Via Accommodation (EVA) Study

2

3 **NCT Number:** NCT03669146

4

5 **Document Date:** January 6, 2024

6 **The Ohio State University Combined Parental Permission and**
7 **HIPAA Authorization for Child's Participation in Research**
8

9 **Study Title:** **Emmetropization Via Accommodation (EVA) Study**
10 **TREATMENT PHASE**

11 **Principal Investigator:** **Ann Morrison, OD, PhD**

12 **Sponsor:** **The Ohio State University College of Optometry**

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

- **This is a parental permission form for research participation.** It contains important information about this study and what to expect if you permit your child to participate. Please consider the information carefully. Feel free to discuss the study with your friends and family and to ask questions before making your decision whether or not to permit your child to participate.
- **Your child's participation is voluntary.** You or your child may refuse participation in this study. If your child takes part in the study, you or your child may decide to leave the study at any time. No matter what decision you make, there will be no penalty to your child and neither you nor your child will lose any of your usual benefits. Your decision will not affect your future relationship with The Ohio State University. If you or your child is a student or employee at Ohio State, your decision will not affect your grades or employment status.
- **Your child may or may not benefit as a result of participating in this study.** Also, as explained below, your child's participation may result in unintended or harmful effects for him or her that may be minor or may be serious depending on the nature of the research.
- **You and your child will be provided with any new information that develops during the study that may affect your decision whether or not to continue to participate.** If you permit your child to participate, you will be asked to sign this form and will receive a copy of the form. You are being asked to consider permitting your child to participate in this study for the reasons explained below.

31 **Key Information About This Study**

32 The following is a short summary to help you decide whether or not your child should be a
33 part of this study. More detailed information is listed later in this form.

34

35 The purpose of this study is to determine if glasses and eye focusing exercises can help babies
36 who are more farsighted than normal at 2 months of age undergo a normal process called
37 emmetropization, which does not always happen in highly farsighted infants. The study is
38 expected to last 15 months and may require your child to wear glasses. There will be a total of
39 seven scheduled visits. There are no major risks of the study, but your child will be dilated at
40 each of their visits. The major benefits of the study is that subjects will receive free eye care
41 for the duration of the study and will receive glasses at no cost, if they are given to your child.

42 If you do not wish to participate in the study, a referral can be made to another eye are
43 provider.

44

45 **1. Why is this study being done?**

46

47 Babies are normally born far-sighted and their eyes undergo a process called
48 emmetropization. Emmetropization is when the eye grows longer during development, so
49 that babies lose their far-sightedness. Sometimes, babies that are more farsighted than
50 normal do not undergo the normal emmetropization process. The purpose of this project is
51 to determine if emmetropization, a normal process that does not always occur in highly
52 farsighted infants can be enhanced by prescribing glasses and performing basic eye
53 focusing exercises at home.

54

55 **2. How many people will take part in this study?**

56

57 A total of 30 subjects will be randomized to either treatment or observation in the study.
58 Half of the subjects, that qualify for randomization ($\geq +5.00$ D - $\leq +7.00$ D) will be
59 randomized to placebo (no-treatment) and the other half will be randomized to partial
60 correction, like flipping a coin. Babies that have a prescription higher than the
61 randomization group ($> +7.00$ D) will be enrolled in a Case Series and all will receive
62 treatment. Up to 10 babies will enrolled in the Case Series.

63

64 **3. What will happen if my child takes part in this study?**

65

66 We will randomize subjects to a treatment group or a placebo group. If the subject is
67 randomized to the treatment group, we will prescribe glasses with a partial correction, an
68 amount that is less than their full degree of farsightedness but may be enough to put them
69 in the zone of 'effective emmetropization'. This "boost" is meant to enable very farsighted
70 babies to use their eyes in a normal way and emmetropize as infants do who are not highly
71 farsighted. This partial correction would be given at 3 months of age. As changes in
72 farsightedness occur, the power of the glasses will be reduced at follow-up visits to keep
73 the farsightedness within the target zone of effective emmetropization. If an infant reaches
74 a normal amount of farsightedness during the study, glasses will be discontinued. The
75 comparison group will be farsighted babies who receive the current standard care, namely
76 no correction but regular monitoring. The main outcome of the study will be whether there
77 is a significant difference in the decrease of farsightedness between the two groups when
78 the infants are 18 months of age.

79

80 This study will require multiple visits over an 18 month period. Seven visits will be
81 scheduled at the following months of age: baseline (3 months), 4 ½, 6, 9, 12, 15, and 18
82 months of age. Each visit will last 1-2 hours and will include drops that will numb the eye
83 and will temporarily make the pupil large (pupil dilation) and prevent the eyes from being
84 able to focus up close (cycloplegia) which will allow for better measurements of the eye.
85 The refractive error (prescription) of the subjects' eyes will be measured while looking

86 straight ahead and while looking off to the side multiple times. The subjects' focusing
87 ability (accommodation), ocular health, and eye alignment will be assessed at every visit.
88

89 **4. How long will my child be in the study?**

90 The study will last for 15 months.
92

93 **5. Can my child stop being in the study?**

95 Your child may leave the study at any time. If you or your child decides to stop
96 participation in the study, there will be no penalty and neither you nor your child will lose
97 any benefits to which you are otherwise entitled. Your decision will not affect your future
98 relationship with The Ohio State University.
99

100 **6. What risks, side effects or discomforts can my child expect from being in the
101 study?**

103 The risks, side effects, or discomforts that may be experienced in this study are the same
104 ones associated with a normal eye examination. The drops used to make your child's pupil
105 large may cause glare and blurred vision at close distances on the day of testing. The blur
106 when reading and sensitivity to bright lights from the dilation typically last for 2 to 7
107 hours. Your child will receive sunglasses for comfort.
108

109 **7. What benefits can my child expect from being in the study?**

111 Your child's high amount of farsightedness may decrease which would decrease the visual
112 burden of the subject and potentially reduce the risk of developing strabismus (crossed
113 eyes) or amblyopia (lazy eye).
114

115 **8. What other choices does my child have if he/she does not take part in the
116 study?**

118 You may choose not to have your child participate without penalty or loss of benefits to
119 which you are otherwise entitled.
120

121 You may take your child to another optometrist or ophthalmologist for a consultation or
122 treatment. You or your child may choose not to participate without penalty or loss of
123 benefits to which you are otherwise entitled.
124

125 **9. What are the costs of taking part in this study?**

127 Costs of taking part in this study are the ordinary time and travel expenses of coming to an
128 appointment at The Ohio State University College of Optometry.

129

130 **10. Will I or my child be paid for taking part in this study?**

131

132 You will be given \$40 cash for each visit at the conclusion of the visit. If your child is
133 randomized to the glasses correction arm of the study, frames and lenses will be provided
134 to you. If the lenses have to be changed during the study, this will also be provided. By
135 law, payments to subjects are considered taxable income.

136

137 **11. What happens if my child is injured because he/she took part in this study?**

138

139 If your child suffers an injury from participating in this study, you should notify the
140 researcher or study doctor immediately, who will determine if your child should obtain
141 medical treatment at The Ohio State University Medical Center, Riverside Pediatric
142 Associates, or The Ohio State University College of Optometry.

143

144 The cost for this treatment will be billed to you or your medical or hospital insurance. The
145 Ohio State University has no funds set aside for the payment of health care expenses for
146 this study.

147

148 **12. What are my child's rights if he/she takes part in this study?**

149

150 If you and your child choose to participate in the study, you may discontinue participation
151 at any time without penalty or loss of benefits. By signing this form, you do not give up
152 any personal legal rights your child may have as a participant in this study.

153

154 You and your child will be provided with any new information that develops during the
155 course of the research that may affect your decision whether or not to continue
156 participation in the study.

157

158 You or your child may refuse to participate in this study without penalty or loss of
159 benefits to which you are otherwise entitled.

160

161 An Institutional Review Board responsible for human subjects research at The Ohio State
162 University reviewed this research project and found it to be acceptable, according to
163 applicable state and federal regulations and University policies designed to protect the
164 rights and welfare of research participants.

165

166 **13. Will my child's de-identified information (and bio-specimens) be used or
167 shared for future research?**

168

169 Yes, it/they may be used or shared with other researchers without your additional
170 informed consent.

171

172 **14. Will my child's study-related information be kept private?**

173

174 Efforts will be made to keep your child's study-related information confidential.
175 However, there may be circumstances where this information must be released. For
176 example, personal information regarding your child's participation in this study may be
177 disclosed if required by state law.

178

179 Also, your child's records may be reviewed by the following groups (as applicable to the
180 research):

- 181 • Office for Human Research Protections or other federal, state, or international
182 regulatory agencies;
- 183 • U.S. Food and Drug Administration;
- 184 • The Ohio State University Institutional Review Board or Office of Responsible
185 Research Practices;
- 186 • The sponsor supporting the study, their agents or study monitors; and
- 187 • Your insurance company (if charges are billed to insurance).

188

189 If we find information that significantly impacts your child's health, we **will** share it with
190 you. This would include any abnormal findings on health examinations or during
191 screening.

192

193 A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as
194 required by U.S. law. This website will not include information that can identify you. At
195 most, the website will include a summary of the results. You can search the website at
196 any time.

197

198 **15. HIPAA AUTHORIZATION TO USE AND DISCLOSE INFORMATION FOR
199 RESEARCH PURPOSES**

200

201 **I. What information about my child may be used and given to others?**

202

- 203 • Past and present medical records;
- 204 • Research records;
- 205 • Records about phone calls made as part of this research;
- 206 • Records about your child's study visits;
- 207 • Information that includes personal identifiers, such as your child's name, or a
208 number associated with your child as an individual;

209

210 **II. Who may use and give out information about your child?**

211

212 Researchers and study staff.

213

214 **III. Who might get this information?**

215

216 • The sponsor of this research. "Sponsor" means any persons or companies that are:

217 • working for or with the sponsor; or

218 • owned by the sponsor.

219 • Authorized Ohio State University staff not involved in the study may be aware that

220 your child is participating in a research study and have access to your child's

221 information;

222 • If this study is related to your child's medical care, study-related information may

223 be placed in your child's permanent hospital, clinic or physician's office record;

224 • Others: staff members and doctors practicing at Riverside Pediatric Associates..

225 **IV. Your child's information may be given to:**

226

227 • The U.S. Food and Drug Administration (FDA), Department of Health and Human

228 Services (DHHS) agencies, and other federal and state entities;

229 • Governmental agencies in other countries;

230 • Governmental agencies to whom certain diseases (reportable diseases) must be

231 reported; and

232 • The Ohio State University units involved in managing and approving the research

233 study including the Office of Research and the Office of Responsible Research

234 Practices.

235 **V. Why will this information be used and/or given to others?**

236

237 • To do the research;

238 • To study the results; and

239 • To make sure that the research was done right.

240 **VI. When will my permission end?**

241 There is no date at which your permission ends. Your child's information will be used

242 indefinitely. This is because the information used and created during the study may be

243 analyzed for many years, and it is not possible to know when this will be complete.

244 **VII. May I withdraw or revoke (cancel) my permission?**

245 Yes. The authorization will be good for the time period indicated above unless you change

246 your mind and revoke it in writing. You may withdraw or take away your permission to

247 use and disclose your child's health information at any time. You do this by sending

248 written notice to the researchers. If you withdraw your permission, your child will not be

249 able to stay in this study. When you withdraw your permission, no new health information

256 identifying your child will be gathered after that date. Information that has already been
257 gathered may still be used and given to others.

259 **VIII. What if I decide not to give permission to use and give out my child's
260 health information?**

262 Then your child will not be able to be in this research study and receive research-related
263 treatment. However, if your child is being treated as a patient here, your child will still be
264 able to receive care.

266 **IX. Is my child's health information protected after it has been given to
267 others?**

269 There is a risk that your child's information will be given to others without your
270 permission. Any information that is shared may no longer be protected by federal privacy
271 rules.

273 **X. May I review or copy my child's information?**

275 Signing this authorization also means that you may not be able to see or copy your child's
276 study-related information until the study is completed.

279 **15. Who can answer my questions about the study?**

281 For questions, concerns, or complaints about the study, or if you feel your child has been
282 harmed as a result of study participation, you may contact:

285 Donald O. Mutti, OD, PhD
286 OSU Study Key Personnel
287 338 West 10th Avenue
288 Columbus, OH 43210-1240
289 Phone: 614-247-7057
290 Email: mutti.2@osu.edu

Ann Morrison, OD, PhD
OSU Clinic Site Principal Investigator
338 West 10th Avenue
Columbus, OH 43210-1240
Phone: 614-247-0010
Email: morrison.421@osu.edu

293 For questions related to your child's privacy rights under HIPAA or related to this
294 research authorization, please contact:

296 Cathy Beatty
297 College of Optometry Privacy Officer
298 338 West 10th Avenue
299 Columbus, OH 43210-1240

300 Phone: 614-247-6190
301 Email: beatty.22@osu.edu

303 For questions about your child's rights as a participant in this study or to discuss other
304 study-related concerns or complaints with someone who is not part of the research team,
305 you may contact the Office of Responsible Research Practices at 1-800-678-6251.

307 If your child is injured as a result of participating in this study or for questions about a
308 study-related injury, you may contact:

310 Donald O. Mutti, OD, PhD
311 OSU Study Key Personnel
312 338 West 10th Avenue
313 Columbus, OH 43210-1240
314 Phone: 614-247-7057
315 Email: mutti.2@osu.edu

310 Ann Morrison, OD, PhD
311 OSU Clinic Site Principal Investigator
312 338 West 10th Avenue
313 Columbus, OH 43210-1240
314 Phone: 614-247-0010
315 Email: morrison.421@osu.edu

319 **Signing the parental permission form**

320
321 I have read (or someone has read to me) this form and I am aware that I am being asked to
322 provide permission for my child to participate in a research study. I have had the opportunity
323 to ask questions and have had them answered to my satisfaction. I voluntarily agree to permit
324 my child to participate in this study.

325
326 I am not giving up any legal rights by signing this form. I will be given a copy of this
327 combined consent and HIPAA research authorization form.

328
Printed name of subject

Printed name of person authorized to provide permission for
subject

Signature of person authorized to provide permission for
subject

Relationship to the subject

Date and time

AM/PM

329
330 **Investigator/Research Staff**

331 I have explained the research to the participant or his/her representative before requesting the
332 signature(s) above. There are no blanks in this document. A copy of this form has been given
333 to the participant or his/her representative.

334
335
336 Printed name of person obtaining consent

Signature of person obtaining consent

AM/PM

Date and time

337
338 **Witness(es) - May be left blank if not required by the IRB**

339
340 Printed name of witness

Signature of witness

AM/PM

Date and time

Printed name of witness

Signature of witness

AM/PM

Date and time